Skip Navigation



Japanese Journal of Clinical Oncology Advance Access published online on April 20, 2009
Japanese Journal of Clinical Oncology, doi:10.1093/jjco/hyp033
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
39/7/413    most recent
hyp033v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Koiwai, K.
Right arrow Articles by Kadoya, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koiwai, K.
Right arrow Articles by Kadoya, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2009). Published by Oxford University Press. All rights reserved

Risk Factors for Severe Dysphagia after Concurrent Chemoradiotherapy for Head and Neck Cancers

Keiichiro Koiwai, Naoto Shikama, Shigeru Sasaki, Atsunori Shinoda and Masumi Kadoya

Department of Radiology, Shinshu University School of Medicine, Matsumoto, Nagano, Japan

For reprints and all correspondence: Keiichiro Koiwai, Department of Radiology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan. E-mail: kkoiwai{at}shinshu-u.ac.jp

Received January 20, 2009; accepted March 15, 2009

Objective: The aim of this study was to investigate the risk factors for dysphagia induced by chemoradiotherapy for head and neck cancers.

Methods: Forty-seven patients with head and neck cancers who underwent definitive chemoradiotherapy from December 1998 to March 2006 were reviewed retrospectively. Median age was 63 years (range, 16–81). The locations of the primary lesion were as follows: larynx in 18 patients, oropharynx in 11, nasopharynx in 7, hypopharynx in 7 and others in 4. Clinical stages were as follows: Stage II in 20 and Stages III–IV in 27. Almost all patients underwent platinum-based concomitant chemoradiotherapy. The median cumulative dose of cisplatin was 100 mg/m2 (range, 80–300) and median radiation dose was 70 Gy (range, 50–70).

Results: Severe dysphagia (Grade 3–4) was observed in 22 patients (47%) as an acute toxic event. One patient required tube feeding even at 12-month follow-up. In univariate analysis, clinical stage (III–IV) (P = 0.017), primary site (oro-hypopharynx) (P = 0.041) and radiation portal size (>11 cm) (P < 0.001) were found to be associated with severe dysphagia. In multivariate analysis, only radiation portal size was found to have a significant relationship with severe dysphagia (P = 0.048).

Conclusions: Larger radiation portal field was associated with severe dysphagia induced by chemoradiotherapy.

Key Words: toxicity • combined modality therapy • head and neck neoplasm • dysphagia • radiotherapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.